Lifetime Television to feature XenaCare Holdings' OTC pain reliever Cobroxin

XenaCare Holdings, Inc. (OTCBB:XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be featured on a segment of The Balancing Act, a morning show that airs on the top-rated women's cable television network, Lifetime Television.

“We look forward to working closely with The Balancing Act's hosts, Beth Troutman and Kristy Villa, to help continue to educate viewers about Cobroxin and its added benefits over traditional pain relievers”

"As the only morning show in the United States dedicated specifically to educating, inspiring and empowering women, The Balancing Act reaches an important segment of Cobroxin consumers," commented Frank Rizzo, President and CEO of XenaCare Holdings. "We look forward to working closely with The Balancing Act's hosts, Beth Troutman and Kristy Villa, to help continue to educate viewers about Cobroxin and its added benefits over traditional pain relievers," he concluded.

The upcoming segment, slated to air on May 17, 2010, and May 31, 2010, will feature an interview with Rik J Deitsch, the Chairman and CEO of Nutra Pharma Corporation (OTCBB: NPHC), the company that developed and currently manufactures Cobroxin. Additionally, it will explore the benefits to using Cobroxin and showcase testimonials from Cobroxin users.

Source XenaCare Holdings

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Soft drinks worsen menstrual pain, study shows